108228-81-5

Basic information

• Product Name: Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester
• CAS NO: 108228-81-5
• Molecular Formula: C12H18BrO3P
• Molecular Weight: 321.151
• Mol File: 108228-81-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester(108228-81-5)
• EPA Substance Registry System: Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester(108228-81-5)

Safety Data

• Hazardous Substances Data: 108228-81-5(Hazardous Substances Data)

Usage

General Description

Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester, is a chemical compound that is commonly used as a pesticide and as an intermediate in the production of pharmaceuticals. It is a diethyl ester of phosphonic acid and contains a bromomethylphenylmethyl group. Phosphonic acid, [[4-(bromomethyl)phenyl]methyl]-, diethyl ester is known for its ability to inhibit the growth of various pests and weeds, making it valuable in agricultural and horticultural applications. It is important to handle this chemical with caution, as it can be harmful if ingested or inhaled, and can cause skin and eye irritation upon contact. Additionally, it may have long-term effects on aquatic organisms if released into the environment.

Upstream product

• 104-81-4 4-Methylbenzyl bromide 
• 623-24-5 1,4-bis(bromomethyl)benzene 
• 3762-25-2 diethyl 4-methylbenzylphosphonate 
• 122-52-1 triethyl phosphite 

Downstream Products

• 142348-55-8 (2S)-2-[(tert-butoxycarbonyl)amino]-3-{4-[(diethoxyphosphoryl)methyl]phenyl}propanoic acid 
• 213127-70-9 diethyl {4-[3-hydroxy-2-(hydroxymethyl)propyl]phenyl}methylphosphonate 
• 213127-80-1 (2R)-2-[4-(diethoxyphosphorylmethyl)benzyl]-3-hydroxypropyl acetate 
• 213127-90-3 (2S)-3-acetoxy-2-{4-[(diethoxyphosphoryl)methyl]benzyl}propanoic acid 
• 213127-76-5 3-acetoxy-2-{4-[(diethoxyphosphoryl)methyl]benzyl}propyl acetate 
• 213127-96-9 diethyl [(4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-hydroxypropyl}phenyl)methyl]phosphonate 
• 213128-01-9 diethyl [{4-[(2R)-3-[(tert-butoxycarbonyl)amino]-2-(hydroxymethyl)propyl]phenyl}methyl]phosphonate 
• 213127-94-7 (2S)-2-[(tert-butoxycarbonyl)amino]-3-{4-[(diethoxyphosphoryl)methyl]phenyl}propyl acetate 
• 213127-98-1 (2R)-3-[(tert-butoxycarbonyl)amino]-2-{4-[(diethoxyphosphoryl)methyl]benzyl}propyl acetate 
• 213127-92-5 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{4-[(diethoxyphosphoryl)methyl]phenyl}propyl acetate 

Relevant articles and documents

Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection

Novel 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles were designed and synthesized as Ebola virus inhibitors. The proposed structures of the new prepared benzimidazole-piperidine hybrids were confirmed based on their spectral data and CHN analyses. The target compounds were screened in vitro for their anti-Ebola activity. Among tested molecules, compounds 26a (EC50=0.93 μM, SI = 10) and 25a (EC50=0.64 μM, SI = 20) were as potent as and more selective than Toremifene reference drug (EC50 = 0.38 μM, SI = 7) against cell line. Data suggests that the mechanism by which 25a and 26a block EBOV infection is through the inhibition of viral entry at the level of NPC1. Furthermore, a docking study revealed that several of the NPC1 amino acids that participate in binding to GP are involved in the binding of the most active compounds 25a and 26a. Finally, in silico ADME prediction indicates that 26a is an idealy drug-like candidate. Our results could enable the development of small molecule drug capable of inhibiting Ebola virus, especially at the viral entry step.

BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION

The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

Selective inhibition of Trypanosoma cruzi GAPDH by "bi-substrate" analogues

A new series of "bi-substrate" analogues have been synthesized as potential inhibitors of the glyceraldehyde-3-phosphate dehydrogenase and one lead compound has been identified that inhibits the enzyme from Trypanosoma cruzi with good affinity and very high (50-fold) specificity. The Royal Society of Chemistry 2005.